Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POLIVY vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Polivy is an antibody-drug conjugate (ADC) composed of a CD79b-directed monoclonal antibody (polatuzumab vedotin) conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE). Upon binding to CD79b on B-cells, the ADC is internalized and MMAE is released via proteolytic cleavage, leading to cell cycle arrest and apoptosis.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
In combination with bendamustine and rituximab for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior therapies.,In combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
1.8 mg/kg intravenously every 21 days in combination with bendamustine and rituximab for up to 6 cycles.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
The terminal elimination half-life of polatuzumab vedotin is approximately 12 days (range 8–20 days) for the antibody-drug conjugate. This supports a dosing interval of every 3 weeks. The half-life may be prolonged in patients with severe hepatic impairment.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
MMAE is primarily metabolized via CYP3A4/5. Less than 10% is metabolized by other CYP isoforms (1A2, 2C9, 2D6, 2E1, 3A4).
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Polivy (polatuzumab vedotin) is eliminated primarily through catabolism into small peptides and amino acids. The antibody-drug conjugate is not significantly excreted renally as intact compound; approximately <1% of the dose is excreted unchanged in urine. The majority of the drug is metabolized and eliminated via biliary/fecal routes, with approximately 80% of the total dose recovered in feces over 3 weeks, primarily as metabolites.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
The conjugate is highly protein-bound (>97%), primarily to plasma proteins such as albumin. The free drug (unconjugated MMAE) is approximately 70–80% bound to albumin.
Approximately 85-90% bound to serum albumin.
The volume of distribution at steady state is approximately 3.4 L (range 2.8–5.6 L), which corresponds to about 0.049 L/kg (assuming 70 kg). This small Vd indicates limited extravascular distribution, consistent with a large antibody-drug conjugate that remains primarily in the vascular space.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Bioavailability is 100% for the intravenous route. No oral formulation exists; the drug is administered only as an intravenous infusion.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate or severe hepatic impairment (Child-Pugh B or C).
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
Safety and efficacy not established in pediatric patients.
Not established; safety and efficacy not determined in pediatric patients.
No specific dose adjustment recommended for elderly patients; monitor for increased toxicity, particularly infections and myelosuppression.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
No FDA black box warning.
None.
Peripheral neuropathy: Monitor for new or worsening neuropathy; may require dose modification or discontinuation.,Infusion-related reactions: Premedicate with antihistamines and antipyretics; monitor during infusion.,Myelosuppression: Neutropenia, thrombocytopenia, and anemia; monitor blood counts regularly.,Infections: Increased risk of serious infections, including opportunistic infections.,Hepatotoxicity: Elevations of liver enzymes; monitor liver function.,Pneumonitis: Interstitial lung disease; monitor for pulmonary symptoms.,Tumor lysis syndrome: Monitor patients at risk and manage accordingly.,Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Concomitant use with strong CYP3A4 inhibitors or inducers (avoid due to potential alteration of MMAE exposure).,Hypersensitivity to polatuzumab vedotin or any component of the formulation.
Hypersensitivity to AURLUMYN or any of its components.
No specific food interactions have been reported. Maintain adequate hydration. Avoid grapefruit or grapefruit juice if also taking certain CYP3A4 substrates, but no direct interaction with POLIVY.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
Based on its mechanism of action as an antibody-drug conjugate targeting CD79b, POLIVY (polatuzumab vedotin-piiq) is expected to cause fetal harm when administered to pregnant women. There are no adequate and well-controlled studies in pregnant women. Verifies embryolethal and teratogenic effects in animal studies. The drug should be avoided during pregnancy, and women of reproductive potential should use effective contraception during treatment and for at least 3 months after the final dose.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
There is no information regarding the presence of polatuzumab vedotin in human milk, its effects on the breastfed infant, or its effects on milk production. Due to the potential for serious adverse reactions in nursing infants, advise women not to breastfeed during treatment with POLIVY and for at least 3 months after the final dose. M/P ratio is not known.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
No specific dose adjustment recommendations are available for pregnancy due to lack of pharmacokinetic data in pregnant women. The drug is not recommended for use during pregnancy. If treatment must be administered during pregnancy, use the standard adult dose based on body weight (1.8 mg/kg actual body weight) as a 90-minute IV infusion every 21 days in combination with other agents. Monitor for toxicity and consider dose modifications for adverse events per standard guidelines.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
POLIVY (polatuzumab vedotin-piiq) is an antibody-drug conjugate targeting CD79b, used in combination with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Monitor for infusion-related reactions, peripheral neuropathy, and myelosuppression. Pre-medicate with antihistamines and antipyretics. Avoid in patients with moderate to severe hepatic impairment.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
This drug is given as an intravenous infusion; you may experience allergic reactions during or after infusion.,Report any numbness, tingling, or weakness in your hands or feet immediately.,You will have regular blood tests to monitor your blood cell counts and liver function.,Use effective contraception during treatment and for at least 3 months after the last dose.,Do not receive live vaccines while on this medication.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POLIVY vs AURLUMYN, answered by our medical review team.
POLIVY is a Antineoplastic Agent that works by Polivy is an antibody-drug conjugate (ADC) composed of a CD79b-directed monoclonal antibody (polatuzumab vedotin) conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE). Upon binding to CD79b on B-cells, the ADC is internalized and MMAE is released via proteolytic cleavage, leading to cell cycle arrest and apoptosis.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POLIVY and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POLIVY is: 1.8 mg/kg intravenously every 21 days in combination with bendamustine and rituximab for up to 6 cycles.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POLIVY and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POLIVY is classified as Category C. Based on its mechanism of action as an antibody-drug conjugate targeting CD79b, POLIVY (polatuzumab vedotin-piiq) is expected to cause fetal harm when administered to pregnant wome. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.